Peptides for Gut Health: The Complete IBS & Leaky Gut Protocol (2026)

Why the Gut Is Peptide Therapy's Sweet Spot

The gut presents a unique opportunity for peptide therapy because several key peptides are effective orally — meaning they can reach the GI lining directly without injection. BPC-157 is acid-stable (derived from gastric juice proteins), KPV has demonstrated oral efficacy in inflammatory bowel models, and LL-37 provides antimicrobial activity relevant to gut pathogen overgrowth.

This guide combines these three peptides into a comprehensive gut protocol addressing the three pillars of gut dysfunction: tissue damage, inflammation, and microbial imbalance.

By Condition

IBS (Irritable Bowel Syndrome)

IBS involves gut-brain axis dysfunction, visceral hypersensitivity, and altered motility — often without visible tissue damage. Peptide approach:

• BPC-157 oral (250-500 mcg/day): Supports gut lining integrity and modulates the gut-brain axis through vagus nerve signaling
• KPV oral (200-500 mcg/day): Reduces low-grade mucosal inflammation that contributes to IBS symptoms
• Selank intranasal (250 mcg 1-2x/day): Addresses the anxiety/stress component of IBS through GABA modulation. Guide →

Leaky Gut (Intestinal Permeability)

Increased intestinal permeability allows bacterial endotoxins and food proteins to cross the gut barrier, triggering systemic inflammation. Peptide approach:

• BPC-157 oral (500 mcg/day): Promotes tight junction repair and mucosal healing
• KPV oral (500 mcg/day): Supports epithelial barrier function and reduces inflammatory mediators that increase permeability

IBD (Crohn's & Ulcerative Colitis)

Inflammatory bowel disease involves active tissue destruction and chronic inflammation. The peptide approach addresses both:

• BPC-157 oral (500 mcg/day): Tissue repair — healing ulcerated mucosa, promoting angiogenesis at damaged sites
• KPV oral (500 mcg 2x/day): Anti-inflammatory — NF-κB pathway inhibition reduces the inflammatory cascade driving tissue destruction. Animal colitis studies showed significant improvement.
• Thymosin Alpha-1 (1.6 mg SC 2x/week): Immune modulation for the autoimmune component. Guide →

SIBO (Small Intestinal Bacterial Overgrowth)

SIBO involves bacteria colonizing the small intestine where they shouldn't be. Standard treatment is antimicrobials (rifaximin, herbal protocols). Peptides can support:

• LL-37 (50-100 mcg SC): Antimicrobial activity + biofilm disruption for resistant SIBO. Guide →
• BPC-157 oral (250 mcg/day): Supports gut motility (impaired motility is a root cause of SIBO recurrence) and heals mucosal damage from bacterial overgrowth

The Complete Gut Protocol

Oral Delivery Advantage

For gut-specific conditions, oral delivery isn't a compromise — it's optimal. The peptide reaches the target tissue (the intestinal lining) directly:

• BPC-157: Uniquely acid-stable among peptides. Survives the stomach and reaches the intestinal mucosa intact.
• KPV: Demonstrated oral efficacy in animal colitis models. Reaches inflamed intestinal tissue directly.
• No injection required for the core gut protocol — making this the most accessible peptide protocol available.

Full delivery method comparison: Oral vs Injectable Peptides Guide

Where to Source

Related Articles